Abstract
Nerve damage during surgery is a common and serious complication, often leading to chronic pain, functional impairments, and diminished quality of life. However, existing methods for intraoperative nerve identification remain insufficient, especially for detecting small or hidden nerve branches. Here we present a new application of a clinically approved fluorescent agent, sodium fluorescein, to enhance nerve visualization during surgery. Utilizing both clinical and customized imaging systems, fluorescein remarkably improved nerve contrast, revealing structures undetectable with white light, including small branches embedded within tissues. With its established safety profile, low cost, and immediate clinical applicability, sodium fluorescein offers the potential to revolutionize surgical practice by minimizing nerve injuries and improving patient outcomes. Clinical Trial Registration: NCT06054178.
Competing Interest Statement
RKP, BAA, OTB, TAV, MMW, MD, JW, JB and OP filed a US provisional patent application. The other authors declare that they have no competing interests.
Clinical Trial
NCT06054178
Funding Statement
The clinical trial at Stanford Hospital and Clinics was funded via support from the National Institute of Communication and Deafness Disorders (NIDCD) grant 5R25DC020174-03 (RKP). RKP, MCL, and MSN were supported by the Stanford Clinician Scientist Training Program. RKP is also supported by the Centralized Otolaryngology Research Efforts (CORE) grant from the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNF). MMW was supported by the German Academic Scholarship Foundation. TAV and OTB were funded by the National Institutes of Health (NIH) through grant no. R01DC021326. OTB was supported by Helmholtz Zentrum München core funding, National Center for Tumor Diseases (NCT) core funding, and the Deutsche Forschungsgemeinschaft (DFG) Emmy Noether program (grant no. BR 5355/2-1), as well as the DFG SFB1123-B10. OTB also received funding from the German Federal Ministry of Education and Research (BMBF) through the BetterView project, from the Helmholtz Imaging Project grant ZT-I-PF-4-038, and from the Annemarie und Richard Wolf-Stiftung. OTB and AC were supported by the Chan Zuckerberg Initiative (CZI) through Deep Tissue Imaging grants DTI0000000248 and DTI2-0000000206, as well as by the EU Horizon Innovation Actions through the PoQus project no. 101189824. OTB, BAA, JB and JW received the NCT Seed Funding in Translational Oncology 2023. OTB, JB, JW and MD were supported by the Else Kröner Fresenius Center for Digital Health (EKFZ) through the LYMPH-EYE project. OTB and OP received funding from the Stiftung Deutsche Krebshilfe through grant no. 70116069.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Stanford University gave ethical approval for this work. The rectal surgery patient in Dresden gave informed consent for the use of fluorescein as an individualized treatment attempt. The scientific analysis of intraoperative imaging data was approved by the Ethics Committee of the Technische Universität Dresden.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.